
Phyteau
abonnés
Onglets principaux
À propos de votre organisation / profil
We are developing safe and effective therapeutics for diabetes, obesity and related metabolic conditions. Our therapeutics work entirely in the gut where they trigger specific enteroendocrine cell receptors causing the release therapeutic levels of key metabolic hormones, including GLP-1, GIP, PYY, OXM and CCK. The recent highly-publicized, class-leading Ozempic, Wegovy and Mounjaro, synthetic “GLP-1 analog” drugs mimic the effect of the natural GLP-1 hormone. The natural hormone and its synthetic analogs activate GLP-1 receptors throughout the body to produce significant therapeutic benefit for diabetes and weight. Your own hormones work naturally and safely to control blood sugar, metabolism, appetite, and food intake with superior efficacy.
Our portfolio and pipeline of completely safe and natural biological compounds that fully trigger these receptors allow us to commercialize our technologies in multiple markets around the world. Our product applications include targeted diabetic, diet, medical, functional food and nutrition products and well as consumer nutraceutical therapeutics. These effective products can be made available to consumers for as little as 5% of the cost of the class-leading synthetic GLP-1 analog drugs, while activating the same physiological mechanisms in the body.
Our protected IP includes a method which restricts the agents to the gut and prevents systemic absorption. Not only does this method eliminate any adverse systemic side effects, but it also enhances and extends the activity of our agents in the gut. In addition, our team’s recent research has provided us with complementary methods for re-balancing the unbalanced microbiome in type 2 diabetes patients. We currently have 5 patents with 3 more pending across the EU, US and China. We anticipate filing several more patents.
We completed the Plug and Play accelerator in Silicon Valley in the fall of 2019, and are a graduate of SOSV's RebelBio biotech accelerator in the UK/Ireland. We were identified as a Top 500 global deeptech startup for 2019 by Hello Tomorrow Global Challenge. In addition, Global Health & Pharma (GHP) magazine's 4th annual Healthcare & Pharmaceutical Awards, awarded us, "Leading Innovators in Metabolic Condition Therapeutics 2019".
Notre levée de fonds
Montant recherché 3 000 000 €
Currently raising €3M+ seed round. Using of funds include major consumer market entry and regulatory compliance in EU, China and US for pharmaceutical products.
Montant recherché:
3 000 000 €
Confirmé:
500 000 €
Intentions:
500 000 €
Réseau (0)
Il n'y a pas encore d'organisations dans le réseau.
Activités récentes

Phyteau a mis à jour sa levée de fonds.

Burns Christopher s’est abonné(e) à la page de Phyteau.

Le document de type pitchdeck a été mis à jour dans la dataroom.

Phyteau a publié une levée de fond levée de fonds.

La dataroom a été mise à jour.